---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-031763"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:46:28.717491+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics reports positive Phase 2a interim data for HT-001: 50% reduction in pruritus by Day 21

## Summary
- Mean pruritus score dropped 50% from 1.6 to 0.8 by Day 21 in open-label portion of CLEER-001 Phase 2a trial.
- Rapid symptom relief: mean score improved to 1.0 by Day 7; some patients achieved complete resolution within 21 days.
- HT-001 was well tolerated with no treatment-related serious adverse events reported.
- Director Graig Springer resigned effective April 15, 2025; Wayne Linsley appointed as chair of nominating and governance committee.

## SEC filing metadata
- accession: 0001213900-25-031763
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390025031763/0001213900-25-031763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390025031763/ea0238201-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-031763
- JSON: https://secwatch.observer/filing/0001213900-25-031763.json
- Plain text: https://secwatch.observer/filing/0001213900-25-031763.txt

## Key facts
- Executive change
  Graig Springer resigned as Director at Hoth Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 9, 2025, Graig Springer informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s audit committee, compensation committee and nominating and corporate governance committee effective as of April 15, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390025031763/0001213900-25-031763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.